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Expression and Action of Transforming Growth Factor Beta (TGFb1, TGFb2,
and TGFb3) during Embryonic Rat Testis Development1
Andrea S. Cupp, Grace Kim, and Michael K. Skinner2
Center for Reproductive Biology, Department of Genetics and Cell Biology, Washington State University,
Pullman, Washington 99164-4231
ABSTRACT
The objective of the current study was to determine the role
of transforming growth factor beta (TGFb) during seminiferous
cord formation and embryonic testis development. The expres-
sion pattern of mRNA for TGFb isoforms was evaluated during
testis development through a quantitative reverse transcription-
polymerase chain reaction (QRT-PCR) procedure. Expression of
mRNA for TGFb1 was highest at postnatal day 0 (P0) and P10.
In contrast, TGFb2 was high at embryonic day 15 (E15), de-
clined at E16, and showed a transient increase at P0 through P3
of testis development. Interestingly, expression of mRNA for
TGFb3 was high during embryonic development and then de-
clined after P3. Immunohistochemical localization of TGFb1
and TGFb2 demonstrated expression in Sertoli cells at E14 and
in the seminiferous cords at P0. Selective interstitial cells ex-
pressed high concentrations of TGFb1 and TGFb2 in P0 testis.
TGFb3 was expressed in selective cells at the junction of the
E14 testis and mesonephros. The cells expressing TGFb3 in the
testis appeared to be preperitubular cells that resided around
the seminiferous cords. TGFb3 was localized to gonocytes in P0
testis. TGFb1 was found to have no influence on seminiferous
cord formation in embryonic organ cultures of E13 testis. In
contrast, growth of both E13 and E14 embryonic organ cultures
was inhibited by TGFb1 and resulted in reduced testis size (40%
of controls) with fewer cords present. A P0 testis cell culture
and thymidine incorporation assay were used to directly exam-
ine the effects of recombinant TGFb1. TGFb1 alone had no in-
fluence on thymidine incorporation in P0 testis cell cultures
when compared to controls. Interestingly, TGFb1 inhibited epi-
dermal growth factor (EGF), and 10% calf serum stimulated P0
testis cell growth but not FSH-stimulated growth. Therefore,
TGFb1 appears to inhibit testis growth in both the embryonic
and early postnatal periods. The hormonal regulation of TGFb
expression was measured using P0 testis cell cultures and a QRT-
PCR procedure for each TGFb isoform. High concentrations of
EGF stimulated expression of mRNA for TGFb1 after 24 h but
suppressed expression of TGFb3. In contrast, there was no effect
of FSH on TGFb isoform expression. In summary, TGFb regulates
embryonic and P0 testis growth through inhibiting the actions
of positive growth factors such as EGF. In addition, EGF but not
FSH appears to regulate TGFb isoform expression. Combined
observations from the present study demonstrate that TGFb iso-
forms are differentially expressed and appear to be regulators
of testis growth during the embryonic and early postnatal peri-
ods.
INTRODUCTION
Seminiferous cord formation is one of the first critical
events in testis development, occurring at embryonic day
13.5 (E13.5; E0 is the date a vaginal copulation plug was
detected) of gestation in the rat [1]. Both aggregation of
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pre-Sertoli and germ cells within the differentiating gonad
and cellular migration of pre-peritubular cells from the ad-
joining mesonephros [1–4] must occur in order for semi-
niferous cords to form. After seminiferous cord formation,
all cell populations within the testis proliferate, and by E15
the testis is twice the size of the ovary from animals of the
same age [5]. Growth and proliferation of cells within the
testis are necessary to allow for adequate numbers of so-
matic cells to support adult germ cell maturation and func-
tion. [6]. All somatic cell populations proliferate during em-
bryonic testis development. In contrast, the germ cell pop-
ulation undergoes mitotic arrest around E17-E18 and by
postnatal day 5 (P5) resumes cellular proliferation [7]. Ear-
ly growth of the embryonic testis is presumed to be inde-
pendent of gonadotropins. Specific binding of gonadotropin
receptors has been detected around E16, but it is unknown
if these receptors have the ability to elicit a response at this
time [8]. Therefore, much of the growth associated with the
testis during early embryonic testis development must be
due to locally produced paracrine growth factors.
Transforming growth factor betas (TGFbs) are critical
for growth regulation and development of many different
cell types within an organism. Of the five TGFb isoforms
identified, three [9–11] are present in mammals (TGFb1,
TGFb2, TGFb3). Each of the TGFb isoforms is encoded
by a unique gene, each on a different chromosome. The
primary functions of the TGFb isoforms are to enhance
formation of the extracellular matrix and inhibit prolifera-
tion of most cells (for reviews see [9, 12]). Inhibition of
growth by TGFb occurs through an arrest of the cell cycle
in late G1 phase and may require interactions with retino-
blastoma and cyclin or cyclin-dependent kinases. The ef-
fects of TGFbs are elicited by activation of two types of
membrane receptors containing serine/threonine kinase ac-
tivity [12, 13], but all TGFb isoforms bind and signal pri-
marily through the TGFb receptor II.
Gene knockout and overexpression experiments with
TGFb have demonstrated that precise regulation of each
isoform is essential for survival. TGFb1 knockouts are phe-
notypically normal until approximately 3 wk after birth and
then develop a severe wasting syndrome [14, 15]. Repro-
ductive traits and organs within TGFb1 isoform knockout
mice have not been extensively studied. However, there are
significant deviations from normal Mendelian ratios, re-
sulting in decreased offspring for both heterozygotes and
homozygotes carrying the allele with the TGFb1 gene dis-
ruption. Thus, TGFb1 may be important in reproductive
function or embryonic development.
Both TGFb1 and TGFb2 have been localized to the so-
matic cells in early embryonic testis [16–18], with receptor
localization within the germ cells [19]. Before birth, the
TGFb2 isoform is also detected within the germ cells [18].
The primary functions of TGFb isoforms during embryonic
testis development are regulation of steroidogenesis within
Leydig cells [20] and potential regulation of germ cell ap-
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optosis [19]. Since TGFb isoforms are present in somatic
cells of the testis during early embryonic development,
their presence may be necessary for cell-cell interactions
that occur during the morphological process of cord for-
mation or embryonic testis growth.
In the current study, the expression of TGFb isoforms
during embryonic testis development was examined. In ad-
dition, two critical time points were evaluated to determine
the actions of TGFb during testis development. The first
was E13-E14, when seminiferous cord formation occurs.
The second time was P0, when cells of the testis are ac-
tively proliferating. The hypothesis tested was that TGFb1,
TGFb2, and TGFb3 have critical roles in testis develop-
ment and are necessary for normal cell-cell interactions




Timed pregnant Sprague-Dawley rats were obtained
from Charles River (Wilmington, MA). For E13 dissec-
tions, gonads were dissected out with the mesonephros, and
for later-stage dissections testes alone were dissected. The
organs were cultured in drops of medium on Millicell CM
filters (Millipore, Bedford, MA) floating on the surface of
0.4 ml of CMRL 1066 medium (Gibco BRL, Gaithersburg,
MD) supplemented with penicillin-streptomycin, insulin
(10 mg/ml), and transferrin (10 mg/ml). Antibodies and fac-
tors were added directly to the culture medium. The me-
dium was changed every day. E13 gonad 1 mesonephros
cultures were typically kept for 3 days, by which time point
cords are well developed. E14 testes were kept for 3 days,
and cords were formed before dissection and organ culture.
Genomic DNA Isolation and Polymerase Chain Reaction
(PCR) for SRY
To determine the sex of E13 gonads, PCR for SRY was
examined. Embryonic tails were collected to make genomic
DNA by standard procedures. Briefly, the tissue was ho-
mogenized through a 25-gauge needle in digestion buffer
(100 mM NaCl, 10 mM Tris pH 8, 25 mM EDTA, 0.5%
SDS) and digested with proteinase K (0.15 mg/ml) for at
least 4 h at 608C. The samples were then extracted twice
with an equal volume of phenol:chloroform:isoamyl alco-
hol (25:24:1), and once with chloroform:isoamyl alcohol.
The DNA was then precipitated by adding a 1/10 volume
of 7.5 M NH4Ac and 3 volumes cold ethanol, and incu-
bating at 2808C for 1 h before centrifugation at 48C for 30
min. Pellets were dried and resuspended in 10 ml dH2O.
PCR was performed using 1 ml of genomic DNA with
primers to SRY. The sequences of the SRY primers are: 59
CGGGATCCATGTCAAGCGCCCCATGAATGCATT-
TATG 39 and 59 GCGGAATTCACTTTAGCCCTCCGAT-
GAGGCTGATAT 39. PCR was performed using an an-
nealing temperature of 558C for 30 cycles to yield a product
of 240 base pairs (bp) [21].
P0 Testis Culture and Growth Assay
To generate a testicular culture from P0 testis, the tunica
was removed, and the testis was digested with 0.125% tryp-
sin, 0.1% EDTA, and 0.02 mg/ml deoxyribonuclease (DN-
ase) in Hanks’ Balanced Salt Solution (HBSS) for 15 min
at 378C. The trypsin was inactivated with 10% calf serum.
The samples were triturated with a pipette tip and washed
twice in 1 ml HBSS by resuspending, spinning for 2 min,
and removing the supernatant. The remaining cell pellet
was resuspended and used immediately in growth assays or
plated in 100-mm plates in F12 medium supplemented with
10% bovine calf serum until confluent (approximately two
days). Cells were plated at a 25% confluency in 24-well
plates and allowed to settle overnight in Dulbecco’s Mod-
ified Eagle’s medium (DMEM) without thymidine. Medium
was replaced the next day, and cells were treated for 24 h
with different hormones or growth factors. Media were re-
moved after the 24-h treatment period, and medium con-
taining tritiated thymidine (10 mCi/ml) was placed on cells
and allowed to remain for 6 h. After 6 h, media were dis-
carded, and cells were either frozen or processed using the
following tritiated thymidine assay. A solution of 0.5 M
NaH2PO4 (pH 7.3; 500 ml) was added to each well, and
cells were sonicated. Half of the sonicated cells were placed
on DE-81 filters on a manifold, and a vacuum was applied.
After three washes with the NaH2PO4 buffer (vacuum ap-
plied after each wash) the filters were dried, placed in
counting vials with 5 ml of scintillation fluid, and counted.
The remaining sonicate was then used for DNA assays to
normalize number of cells (DNA) per well [22].
DNA Assay
To assay the DNA content of organs, each organ was
sonicated in 100 ml ethidium bromide buffer (EBB; 20 mM
NaCl, 5 mM EDTA, 10 mM Tris pH 7.5) and stored at
2208C. DNA content then was determined fluorometrically
with ethidium bromide as previously described [22]. Brief-
ly, 0.25 nM ethidium bromide and 100 U/ml heparin in
EBB were added to each sample, vortexed, and incubated
for 15 min at room temperature. Fluorescent emission was
measured and quantified by using a standard curve with
calf thymus DNA from 0.5 mg to 6 mg DNA. For growth
assays, the above procedure was used on remaining soni-
cate from the tritiated thymidine procedure [22].
Imaging and Area Analysis
Images of whole organs were obtained by using an im-
age analysis system (Pixera; Pixera Corp., Los Gatos, CA;
[22]). Areas were quantified using the NIH image program.
Previous data correlated DNA concentrations of testis organ
cultures with the area imaged by the NIH image program
[23]. Each testis (without mesonephros) was outlined three
times, and the areas of these outlines were averaged to ob-
tain accurate area measurements. The averages for the con-
trol testis organ cultures were set to 100%, and the area of
a treated testis was calculated as a percentage of its paired
control. Approximately 18 testis pairs for the E14 testis
organ cultures (three experiments with 6 testis pairs per
experiment) and 36 testis pairs for the E13 testis organ
cultures (4 experiments with 6 testis pairs per experiment)
were imaged for area quantifications. Areas for each age
were averaged and presented as a percentage of their re-
spective controls.
RNA Isolation and Quantitative Reverse Transcription
(RT)-Polymerase Chain Reaction (PCR)
RNA for RT-PCR was extracted from tissue using Tri
Reagent (Sigma, St. Louis, MO) for RNA isolation. RT and
quantitative RT-PCR (QRT-PCR) procedures were utilized
as previously published [22]. Briefly, for QRT-PCR, total
RNA (1 mg) was reverse-transcribed using the specific 39-
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primers of interest. Carrier DNA (Bluescript plasmid; Stra-
tagene, La Jolla, CA) was added to a final concentration of
10 ng/ml. Plasmid DNAs containing standard subclones of
interest were used to generate standard curves from 1 ng/
ml (10215 g/ml) to 10 pg/ml (10 3 1029 g/ml), each con-
taining 10 ng/ml Bluescript carrier DNA. Identical 10-ml
aliquots of each sample and standard were used for PCR
amplification. By this design it was possible to simulta-
neously assay 5 known standard concentrations and 40 un-
known samples for each gene. At least 0.25 mCi of 32P-
labeled dCTP was included in each sample during ampli-
fication. Specific PCR products were quantitated by elec-
trophoresing all samples on 4–5% polyacrylamide gels,
simultaneously exposing the gels to a phosphor screen for
8–24 h, and then quantifying specific bands on a
PhosphorImager (Molecular Dynamics, Sunnyvale, CA).
Each gene was assayed in separate PCR reactions from the
same RT samples. Equivalent steady-state mRNA levels for
each gene were determined by comparing each sample to
the appropriate standard curve. All gene expression data
were normalized for 1B15 (cyclophilin) mRNA. Cyclo-
philin is constitutively expressed in the testis until the
pachytene spermatocytes are present [24]. Since pachytene
spermatocytes first appear around P17–18 of age, measure-
ments at any age after this point should be evaluated with
this limitation considered. The optimal cycle number for
amplification was determined for each assay in order to
achieve maximum sensitivity while maintaining linearity
(i.e., logarithmic phase of PCR reactions). The sensitivity
of each quantitative PCR assay is below 1 fg, with intra-
assay variabilities of 6.0–15%. Primers used for the QRT-
PCR are as follows: TGFb1, 5 prime: 59-TCG ATT TTG
ACG TCA CTG GAG TTG T-39, 3 prime: 59-GGG GTG
GCC ATG AGG AGC AGG-39; TGFb2, 5 prime: 59-CCG
CCC ACT TTC TAC AGA CCC-39, 3 prime: 59-GCG CTG
GGT GGG AGA TGT TAA-39; TGFb3, 5 prime: 59 TGC
CCA ACC CGA GCT CTA AGC G-39, 3 prime: 59 CCT
TTG AAT TTG ATC TCC A-39; cyclophilin, 5 prime: 59
ACA CGC CAT AAT GGC ACT GG-39, 3 prime: 59-ATT
TGC CAT GGA CAA GAT GCC-39 [22].
Embedding, Histology, and Immunohistochemistry
Tissues were fixed in Histochoice (Amresco, Solon, OH)
and embedded in paraffin according to standard procedures
[25, 26]. Sections were stained with hematoxylin and eosin
according to standard procedures [25, 26]. Briefly, 3-mm
sections were deparaffinized and rehydrated, microwaved
(15 min), and blocked in 10% serum for 30 min at room
temperature. Immunocytochemistry was performed as pre-
viously described [22, 25]. The TGFb1 primary antibody
was an anti-TGFb1 peptide antibody (Santa Cruz Biotech-
nology [SCB], Santa Cruz, CA) raised against amino acids
328–353 of human TGFb1 (which is 100% homologous to
mouse TGFb1). The TGFb2 primary antibody was an anti-
TGFb2 peptide antibody (SCB) raised against amino acids
352–377 of human TGFb2. The TGFb3 primary antibody
was an anti-TGFb3 peptide antibody (SCB) raised against
amino acids 350–375 of human TGFb3. The TGFb1 and
TGFb3 antibodies were diluted 1:50 in 10% goat serum;
the TGFb2 primary antibody was diluted 1:1200 in 10%
goat serum. The biotinylated goat anti-rabbit secondary an-
tibody (Vector Laboratories, Burlington, CA) was diluted
1:300. Two negative controls were conducted for each
TGFb isoform. The first negative control involved a serial
section of testis tissue treated as described above, but with
no primary TGFb antibody. The second negative control
involved incubation of each primary antibody with 50- to
100-fold excess of each respective TGFb protein before
application to the tissue; then these tissues were treated as
described above. The secondary antibody was detected by
using the histo stain-sp kit (Zymed Laboratories, South San
Francisco, CA), and immunohistochemical images were
digitized with a slide scanner (Sprint Scan, Polaroid, Cam-
bridge, MA).
Statistical Analysis
All data were analyzed by a JMP 3.1 statistical analysis
program (SAS Institute, Cary, NC). All values are ex-
pressed as the mean 6 SEM. Statistical analysis was per-
formed using one-way ANOVA. Significant differences
were determined using Dunnett’s test for comparison to
controls and using the Tukey-Kramer honestly significant
difference test for multiple comparisons. Statistical differ-
ence was confirmed at p , 0.05.
RESULTS
Characterization of the QRT-PCR Procedure for TGFb
Preliminary studies were performed to establish a repro-
ducible and accurate QRT-PCR procedure [22]. The lineari-
ty of generating a PCR product relative to cycle number
was determined [22]. Thirty cycles was selected as an ap-
propriate cycle number for TGFb1, 33 cycles for TGFb2,
35 cycles for TGFb3, and 25 cycles for cyclophilin [22].
Comparison of standard DNA with unknown samples was
conducted to determine parallel displacement. Plasmid
DNA with subcloned PCR product and cDNA produced
from unknown RNA samples were run in parallel. PCR
products of diluted plasmid DNA and diluted unknown
cDNA were compared. These two curves were parallel with
each growth factor, indicating that the QRT-PCR assay
could be used to quantitate mRNA levels. Minimal vari-
ability of this assay was demonstrated previously [22].
Developmental Regulation of TGFb Expression during
Testis Development
Experiments were designed to investigate the changes in
expression of TGFb1, TGFb2, and TGFb3 from E15
through postnatal day 30 (P30) of testis development.
Whole testes were removed from rats aged E15, E16, E18,
P0, P3, P4, P5, P10, P20, and P30, and the mRNA expres-
sion of TGFb was measured by QRT-PCR [22]. The ex-
pression of TGFb isoforms was quantitated using a stan-
dard curve for each isoform and was normalized by the
expression of the gene cyclophilin, which is constitutively
expressed through P10 of testis development [22], for each
sample. The amount of mRNA for TGFb1 was low early
in embryonic development (E15, p , 0.05); then increased
at E16 (p , 0.05), birth (P0, p , 0.05), and prepuberty
(P10, p , 0.05); and decreased after puberty and into adult-
hood (P20-P30, p , 0.05) (Fig. 1A). In contrast to TGFb1
expression, mRNA for TGFb2 was elevated early in em-
bryonic development (E15, p , 0.05) and then decreased
during the late embryonic period (E16, E18). TGFb2 tran-
siently increased during the early postnatal period (P0-P4)
and decreased during the pubertal and adult stages of testis
development (P5-P30, p , 0.05) (Fig. 1B). Expression pat-
terns for TGFb3 were the most dramatic, with higher con-
centrations of TGFb3 during embryonic testis development
(E16-P0) and significantly lower concentrations during the
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FIG. 1. Relative expression of mRNA for A) TGFb1, B) TGFb2, and C)
TGFb3 during E15 though P30 of testis development. Expression of TGFb
isoforms is normalized for amount of cyclophilin. The mean 1 SEM are
presented for each time period during which RNA was evaluated. Three
to six pooled tissue samples were assayed in duplicate for each devel-
opmental time period in a minimum of three pooled different experi-
ments. Different letters for each developmental time represent statistical
differences at p , 0.05.
postnatal, pubertal, and adult periods (P3-P30, p , 0.05)
(Fig. 1C). In a subsequent study, E14 mRNA was analyzed,
and levels of TGFb isoforms were consistent with those of
E15 (data not shown). Each of the TGFb isoforms had a
different pattern of expression during embryonic testis de-
velopment. This suggests that these TGFb isoforms are dif-
ferentially regulated. The reduction in message for all
TGFb isoforms after puberty (P20–30) may be a dilution
effect of increased number of germ cells in the testis due
to the onset of spermatogenesis, or due to the increased
amount of cyclophilin produced by pachytene spermato-
cytes at these developmental stages [24].
Localization of TGFb during Embryonic Testis
Development
Immunohistochemistry was conducted on testis sections
from E14 and P0 rats to determine expression of TGFb1,
TGFb2, and TGFb3 (Fig. 2, A–H). Sections were evaluated
and cell types were determined by staining of serial sections
for cell-specific antibodies. Negative controls for each an-
tibody were used to determine positively stained cells. Ex-
cess TGFb protein abolished staining for TGFbs 1, 2, and
3 antibodies for the sections evaluated (data not shown). At
E14 there appeared to be more widespread staining of
TGFb1. Positive staining for TGFb1 was present in Sertoli
cells and surrounding gonocytes. However, even at higher
magnification it was not conclusive whether gonocytes
themselves were stained or the Sertoli cells surrounding the
gonocytes were positive for TGFb1 (Fig. 2C). At P0,
TGFb1 was expressed in Sertoli cells surrounding gono-
cytes, in gonocytes, and in some interstitial cells (Fig. 2D).
Staining for TGFb2 was observed to be specific for Sertoli
cells at E14 (Fig. 2E). At P0, TGFb2 was expressed at low
levels in Sertoli cells, and high levels of expression were
observed in selective interstitial cells (Fig. 2F). In contrast,
TGFb3 was expressed in cells bordering the E14 meso-
nephros and testis (Fig. 2G). The intensely stained cells in
E14 testis appeared to be pre-peritubular and to reside
around seminiferous cords. Single cells of the testis inter-
stitium also stained for TGFb3 at E14. Lower-intensity
staining was observed both in mesonephric ducts of the
mesonephros and in specific cells of the testis (Fig. 3, A–
D). This pattern of TGFb3 may provide a marker for mi-
grating cells from the mesonephros. In contrast to TGFb3
expression at E14, TGFb3 was expressed in gonocytes in
the P0 testis (Fig. 2H). Cellular localization of TGFb iso-
forms appeared to be distinct, with changing cellular lo-
calization during embryonic and early postnatal testis de-
velopment. These data complement the QRT-PCR data and
confirm the expression of the TGFb proteins.
TGFb1 Regulation of Embryonic Seminiferous Cord
Formation and Growth
The effects of TGFb1 on seminiferous cord formation
were investigated in E13 testis organ cultures. E13 testes
with mesonephroi were cultured on floating filters in the
presence or absence of 40 ng/ml recombinant TGFb1 for a
3-day period. The testis organ cultures were routinely treat-
ed each day with daily changes of media. The control organ
cultures formed seminiferous cords by the third day of cul-
ture. The dose of 40 ng/ml of TGFb1 was used because it
had been determined previously [22, 23] to be the most
effective dose to inhibit cellular growth in cell culture. Oth-
ers have demonstrated that 10 ng/ml of TGFb1 can also
inhibit cell growth in embryonic testis germ cells [19]. In
the current study, TGFb1 did not inhibit seminiferous cord
formation (Fig. 4, A and B) but did inhibit growth of the
E13 testis organ cultures. The number of seminiferous
cords formed in the TGFb1-treated testis was reduced, but
this was due to the overall reduced size of the testis organ
culture.
To determine the effects of TGFb on growth of testis
organ cultures, the embryonic testes were cultured in the
presence or absence of 40 ng/ml of TGFb1. TGFb1 inhib-
ited growth of the E14 testis organ cultures in a manner
similar to that of the E13 testis organ cultures (Fig. 4, C
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FIG. 2. Immunohistochemistry for control sections at A) E14 and B) P0; TGFb1 at C) E14 and D) P0; TGFb 2 at E) E14 and F) P0; and TGFb3 at G)
E14 and H) P0. Immunohistochemistry was conducted three separate times for each developmental time period. Controls were samples not treated
with primary antibody (A, B) and incubation of excess (50–1003) TGFb protein to suppress signal. 3400: A, B, E, F; 3200: G, C, H; 31000. Reproduced
at 93%. M, Mesonephros; T, testis.
1309TGFb AND EMBRYONIC TESTIS DEVELOPMENT
FIG. 3. Immunohistochemistry for TGFb3 in E14 testis sections. A–B represent two different testis sections (3400). Arrows point to positive stained
cells for TGFb3 surrounding seminiferous cords. C–D) Higher magnification of mesonephros (C) and testis (D) at 31000. Reproduced at 93%. M,
Mesonephros; T, testis; MD, mesonephric duct; C, seminiferous cord.
FIG. 4. A) Control E13 testis organ cul-
tures plus mesonephros, B) E13 testis or-
gan cultures plus mesonephros treated
with 40 ng/ml TGFb1, C) control E14 testis
organ culture, D) E14 testis organ culture
treated with 40 ng/ml of TGFb1. Organ
cultures were either not treated (controls)
or treated daily with 40 ng/ml of TGFb1 at
the time of the daily change in medium
for a 3-day period. These are representa-
tive of E13 organ cultures from 36 pairs of
testes treated (n 5 36), and E14 testis or-
gan cultures from 18 pairs of testes treated
(n 5 18; one control and one treated per
pair). T, Testis; M, mesonephros. Dashed
lines separate testis and mesonephros.
380 (reproduced at 88%).
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FIG. 5. Area of testis expressed as percentage of control for E13 and
E14 testis organ cultures either treated with TGFb or controls. The mean
1 SEM are presented for each developmental age for E13 (n 5 36; 4
replicates with 6 testis pairs per experiment) and E14 testis (n 5 18; 3
replicates with 6 testis pairs per experiment). Different letters for each
mean represent statistical differences at p , 0.05.
FIG. 6. Effect of TGFb1 on cell growth in
P0 testis suspensions. P0 testes were stim-
ulated with FSH (25 ng/ml), EGF (50 ng/
ml), or 10% calf serum alone or with
TGFb1 (40 ng/ml). Data are the combined
results of four independent experiments
conducted in triplicate. Values have been
normalized for DNA/well and are ex-
pressed as percentage of controls with
controls set to 100%. Different letters for
each mean represent statistical differences
at p , 0.05.
and D). The areas of the cultured testes were analyzed, and
a significant reduction in testis size was observed in E13
and E14 cultured testes when compared to matched controls
(approximately 40–50% reduction, p , 0.05; Fig. 5). Pre-
viously, the reduced area has been shown to correlate to a
reduced DNA content in the organ (data not shown). There-
fore, TGFb1 does not alter seminiferous cord formation but
can inhibit testis growth, as demonstrated by the decreased
testis area in TGFb1-treated E13 and E14 testis organ cul-
tures.
TGFb1 Regulation of P0 Testis Cell Growth
The effects of TGFb1 on P0 testis growth were inves-
tigated through a tritiated thymidine incorporation assay to
access cellular growth. Data were normalized to the amount
of DNA for each sample. Mixed populations of P0 testis
cultures were treated with the most effective dose of the
growth factors FSH (25 ng/ml), EGF (50 ng/ml), and 10%
calf serum. All treatments stimulated tritiated thymidine in-
corporation in growth assays conducted on P0 testis cul-
tures (Fig. 6). P0 testis cell cultures were treated with TGFb
alone or with positive regulators of P0 testis growth—FSH,
EGF, and 10% calf serum. TGFb1 (40 ng/ml) treatment
alone at the most effective dose for growth inhibition did
not significantly alter thymidine incorporation into P0 testis
cultures when compared to controls. However, TGFb1 in-
hibited (p , 0.05) EGF- and 10% calf serum-stimulated
thymidine incorporation into P0 testis cultures (p , 0.05;
Fig. 5). Interestingly, TGFb1 did not modulate FSH-stim-
ulated growth in P0 testis cultures. Therefore, TGFb1 can
inhibit growth factor-stimulated growth in P0 testis cultures
(i.e., EGF and 10% calf serum) and may be a potential
regulator of testis growth during this perinatal period.
Hormonal Regulation of TGFb Expression
The effects of positive stimulators of growth (i.e., EGF
and FSH) on expression of TGFb1, TGFb2, and TGFb3
were examined (Fig. 7) in P0 testis cultures using QRT-
PCR. All values were normalized with cyclophilin and ex-
pressed as relative expression compared with that in control
cultures. P0 testis cultures were treated with FSH (25 ng/
ml) and EGF (100 ng/ml), and RNA was collected after 24
h of treatment. EGF significantly stimulated expression of
TGFb1 (p , 0.05) and reduced expression of TGFb3 (p
, 0.05) after a 24-h period relative to controls (Fig. 7).
There was no effect of treatment of P0 testis cultures with
FSH (25–50 ng/ml) on expression of TGFb isoforms 24 h
after stimulation. Therefore, these data demonstrate that
EGF may directly regulate expression of mRNA for TGFb1
and TGFb3 in P0 testis cultures. This regulation may be
part of a negative feedback loop between EGF and TGFb
to modulate testis cell growth and differentiation.
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FIG. 7. Relative amounts of mRNA for TGFb1, TGFb2, and TGFb3 after
24 h of P0 testis cultures with no treatment (control) or treatment with
FSH (25 ng/ml) or EGF (100 ng/ml). Data are combined results of three
different experiments conducted in duplicate. Messenger RNA levels for
each isoform have been normalized to cyclophilin and are relative to
controls for each experiment. Different superscript letters for each rep-
resent statistical differences at p , 0.05.
DISCUSSION
The current study was designed to investigate the action
and expression of TGFb during embryonic testis develop-
ment. Previously, three isoforms of TGFb (TGFb1, TGFb2,
and TGFb3) have been determined to be present in the
postnatal testis [9–12]. In addition, TGFb1 and TGFb2
have been identified in the embryonic testis by immuno-
histochemistry [16–18]. Localization of TGFb1 and TGFb2
in the current study was similar to that in data previously
reported. In previous studies, TGFb1 was found to be pos-
itive in Sertoli cells, but not in gonocytes, in E14.5 testis.
In the current study, E14 testis sections also stained positive
for TGFb1 in Sertoli cells. There was also staining that
surrounded gonocytes at a higher magnification of these
testis sections, but it was unclear as to whether TGFb1 was
present in the gonocytes. At P0, TGFb1 positive staining
was present in Sertoli cells, surrounding gonocytes, and in
selected interstitial cells. No previous reports have de-
scribed TGFb1 staining in P0 testis. Previously, TGFb1 has
been demonstrated to be present in Leydig cells at E16.5,
P4, and P20. The antibodies used in the present study for
TGFb1 were different from those used in previous studies.
Antibody differences may explain these slight localization
differences for TGFb1. Positive staining for TGFb2 was
present at E14 in Sertoli cells, a finding that agrees with
previously published data. In addition, at P0 there were
faint staining for TGFb2 in Sertoli cells and high levels of
staining in selected cells of the interstitium. In addition, the
current study also localized expression of TGFb3 during
embryonic testis development, which previously has not
been reported. TGFb3 was expressed in cells surrounding
seminiferous cords at the testis-mesonephros interface at
E14. Mesonephric ducts within the mesonephros and indi-
vidual interstitial cells within the gonad also expressed
TGFb3 at E14. This pattern of expression of TGFb3 sug-
gests potential cellular interactions between mesonephric
and testicular cells. Previously, it had been shown that cells
migrate from the mesonephros into the testis to participate
in seminiferous cord formation. It appears that pre-peritu-
bular cells and selected interstitial cells stain for TGFb3 at
E14. Therefore, pre-peritubular cells may express TGFb3
to induce migration or differentiation resulting in seminif-
erous cord formation. Interestingly, only cells surrounding
cords adjacent to the mesonephros stained for TGFb3. Fur-
ther investigation is necessary to determine the potential
role of TGFb3 in mesonephric cell migration into the testis.
Expression of TGFb3 in the P0 testis appeared to be in
Sertoli cells with high concentrations localized in gono-
cytes. Therefore, TGFb3 may regulate two distinct devel-
opmental processes at different times during testis devel-
opment.
To extend these data, expression of mRNA for TGFb
isoforms were also evaluated in the current study. Expres-
sion patterns of TGFb1, TGFb2, and TGFb3 are unique
during testis development and do not appear to have over-
lapping expression patterns. Early in embryonic testis de-
velopment (i.e., E15), only TGFb2 expression was high
while the concentrations of mRNA for TGFb1 and TGFb3
were relatively low. There were similar results with E14
testis (data not shown). In addition, expression of TGFb1
was significantly higher at P0 and P10 while expression of
TGFb2 was highest at E15 and P3. Interestingly, TGFb3
has the most distinctive expression pattern, with highest
concentrations observed during embryonic testis develop-
ment. This pattern may indicate an important role of
TGFb3 during embryonic testis development, or it may
have been due to the dilution effect of spermatogenesis dur-
ing the postnatal period. TGFb1 has been reported to be
present in germ cells and Sertoli cells during the postnatal
period, and there was no dramatic change in expression of
mRNA between the embryonic and postnatal periods. It is
not known what the expression pattern of TGFb3 is during
the postnatal period; therefore, if it is present in the somatic
cells, a decrease in expression of this gene would be ob-
served.
Actions of TGFb during embryonic testis development
are thought to be primarily on gonocytes (E14), and by
E16.5 on both Leydig cells and gonocytes [19]. Receptors
for TGFb have been localized to gonocytes and Leydig
cells at these developmental time periods. TGFb1 has been
identified as a regulator of Leydig cell steroidogenesis, and
it can inhibit LH-stimulated testosterone production [20] in
E16.5 testis cultures. Both TGFb1 and TGFb2 have been
demonstrated to induce gonocyte apoptosis around E14 of
embryonic testis development [19]. Therefore, these results
suggest that paracrine and/or autocrine interactions occur
between cells that produce TGFb1 and TGFb2, to regulate
both Leydig and gonocyte functions in the embryonic testis.
The potential action of TGFb on seminiferous cord for-
mation has not been previously reported and is addressed
in the current study. Treatment of E13 testis organ cultures
did not affect seminiferous cord formation in the present
study. However, growth of the embryonic testis organ cul-
tures was inhibited as measured by testis area. A reduction
in seminiferous cord numbers was observed in E13 testis
organ cultures, but this was determined to occur because
of a reduced overall size of the testis. This inhibition of
growth was further demonstrated in E14 testis organ cul-
tures treated with TGFb1, in which a 40% reduction in
testis size compared to that of controls was observed. Pre-
vious reports have demonstrated a similar effect on gono-
cyte numbers with TGFb1 and TGFb2 treatment of E13.5
testis organ cultures. This reduction was demonstrated to
occur through an increase in gonocyte apoptosis [19], and
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no data were included on effects of TGFb on overall testis
size. In the current study, a 40% reduction in testis size in
both E13 and E14 testis organ cultures was observed with
TGFb1. A similar effect would be hypothesized with
TGFb2. It seems unlikely that a 40% reduction in the size
of the testis would occur because of the inhibition of one
cell population alone. The dose of TGFb1 used in these
experiments (40 ng/ml) was greater than in the experiments
previously reported (10 ng/ml) [19]. Additionally, our ex-
periments were conducted for 3 days, with TGFb1 treat-
ments each day. Thus, by the last day of treatment, the
Leydig cells may have obtained receptors for TGFb, caus-
ing a reduction in cellular proliferation within this cell type.
This may explain the dramatic reduction in testis size with-
in the testis organ cultures in the current study. Therefore,
regulation of expression of TGFb1 may be important dur-
ing embryonic testis development to initially regulate germ
cell numbers and later to potentially regulate somatic cell
growth.
TGFb1 is capable of inhibiting early postnatal testis
growth as well as embryonic testis growth. In the current
study, TGFb1 inhibited EGF- and 10% calf serum-stimu-
lated growth in P0 testis cultures. The P0 testis cultures
have a mixed population of cells, and these data must be
interpreted carefully. Both gonocytes and Leydig cells, but
not Sertoli cells, have receptors for TGFb at this time dur-
ing testis development. Treatment of P0 testis cultures with
FSH stimulates tritiated thymidine incorporation, presum-
ably through stimulation of growth of Sertoli cells, which
contain FSH receptors. TGFb1 did not inhibit FSH-stimu-
lated growth but did inhibit EGF- and 10% calf serum-
stimulated growth. Therefore, most of the effects of TGFb1
on inhibition of P0 testis may be elicited through inhibition
of interstitial and/or gonocyte cell growth.
The TGFbs have been reported to stop the cell cycle in
numerous cell types [13, 27] late in G1 when the cell be-
comes committed to enter S phase. Previous literature has
demonstrated that gonocytes undergo mitotic arrest around
E17-E18 and resume mitosis after P5 [28]. TGFb1 and
TGFb2 may contribute to the regulation of this mitotic ar-
rest since they are both highly expressed around P0.
Growth stimulators such as EGF and FSH must either stim-
ulate the expression of genes that promote progression to
the S phase of the cell cycle, or inhibit expression of genes
that halt cell cycle progression. Therefore, in the present
study we hypothesized that EGF and FSH may inhibit
mRNA expression of the TGFb isoforms. EGF did suppress
expression of TGFb3 in P0 testis 24 h after stimulation.
However, most of the data collected in the present study
did not support our hypothesis. FSH stimulation had no
effect on expression of TGFb isoforms. EGF stimulated
expression of TGFb1 and suppressed expression of mRNA
for TGFb3. These observation are interesting since FSH
does not appear to regulate TGFb isoforms while EGF ap-
pears to regulate them differentially. Previous data suggest
overlapping roles for the TGFb isoforms in the regulation
of cell growth and proliferation; however, the current study
suggests a unique regulation of each TGFb isoform by
growth factors.
Interestingly, FSH stimulation of P0 testis was not in-
hibited by TGFb. In addition, FSH treatment did not influ-
ence expression of TGFb isoforms. Potential interactions
have been reported between TGFb1 and LH in the fetal rat
testis. TGFb1 has been demonstrated to inhibit LH-induced
cAMP production and LH-induced testosterone production
in dispersed fetal testis (E16.5) [20]. However, no studies
have demonstrated interactions between FSH and TGFb
isoforms. The results of the current study suggest that there
is no direct regulation of FSH on expression of TGFb iso-
forms in cultures of P0 testis. This may be due to the fact
that Sertoli cells do not appear to contain receptors for
TGFb isoforms. Therefore, TGFb isoforms are incapable
of directly regulating Sertoli cell specific growth. FSH may
also stimulate the expression of factors that stimulate
growth such as TGFa.
It is also interesting that the growth factor EGF can stim-
ulate expression of a growth-inhibitory factor such as
TGFb1 while suppressing TGFb3. This differential regu-
lation of the two isoforms of TGFb may be due to the
different cell types that produce each factor. At P0, TGFb1
is localized to three different cell types while TGFb3 is in
gonocytes. EGF may differentially regulate these cell types.
Increased expression of TGFb1 in response to EGF would
demonstrate a feedback loop between these growth factors.
High concentrations of EGF may act to stimulate TGFb1,
which in turn suppresses EGF-stimulated growth.
The novel results of the current study demonstrate that
TGFb isoforms effect embryonic testis growth through the
regulation of locally produced growth factors. The unique
expression patterns and cellular localization of the TGFb
isoforms during embryonic testis development support a
role for each isoform in the regulation of cellular growth
and differentiation. TGFb regulates embryonic testis
growth through inhibition of growth stimulators such as
EGF. In contrast, EGF regulates expression of mRNA for
TGFb isoforms. Combined observations suggest that the
interactions of paracrine factors such as TGFbs and EGF
allow for optimal cellular growth and differentiation during
embryonic testis development.
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